US Pharma MarketingBiotech value creation at an inflection point
Innovation in life sciences has never been more exciting, but the bar for success is higher than ever. Capital is tighter and expectations are higher. Hear how biotech leaders must rethink value, evidence and deal readiness in 2026.
Capital is tighter and expectations are higher. Hear how biotech leaders must rethink value, evidence and deal readiness in 2026.
Source: FierceBiotech